SK12622002A3 - Farmaceutická kompozícia na báze inhibítorov glykogén fosforylázy - Google Patents
Farmaceutická kompozícia na báze inhibítorov glykogén fosforylázy Download PDFInfo
- Publication number
- SK12622002A3 SK12622002A3 SK1262-2002A SK12622002A SK12622002A3 SK 12622002 A3 SK12622002 A3 SK 12622002A3 SK 12622002 A SK12622002 A SK 12622002A SK 12622002 A3 SK12622002 A3 SK 12622002A3
- Authority
- SK
- Slovakia
- Prior art keywords
- alkyl
- carbon atoms
- composition
- cellulose acetate
- glycogen phosphorylase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18994200P | 2000-03-16 | 2000-03-16 | |
PCT/IB2001/000394 WO2001068055A1 (en) | 2000-03-16 | 2001-03-16 | Pharmaceutical compositions of glycogen phosphorylase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SK12622002A3 true SK12622002A3 (sk) | 2004-02-03 |
Family
ID=22699402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK1262-2002A SK12622002A3 (sk) | 2000-03-16 | 2001-03-16 | Farmaceutická kompozícia na báze inhibítorov glykogén fosforylázy |
Country Status (32)
Country | Link |
---|---|
US (1) | US20010053778A1 (sh) |
EP (1) | EP1263414A1 (sh) |
JP (1) | JP2003526654A (sh) |
KR (1) | KR20020081445A (sh) |
CN (1) | CN1418089A (sh) |
AP (1) | AP2002002621A0 (sh) |
AR (1) | AR027656A1 (sh) |
AU (1) | AU2001242669A1 (sh) |
BG (1) | BG107037A (sh) |
BR (1) | BR0109189A (sh) |
CA (1) | CA2403241A1 (sh) |
CO (1) | CO5280087A1 (sh) |
CZ (1) | CZ20022955A3 (sh) |
EA (1) | EA200200858A1 (sh) |
EE (1) | EE200200530A (sh) |
HU (1) | HUP0204583A2 (sh) |
IL (1) | IL151320A0 (sh) |
IS (1) | IS6508A (sh) |
MA (1) | MA26882A1 (sh) |
MX (1) | MXPA02009097A (sh) |
NO (1) | NO20024386L (sh) |
OA (1) | OA12232A (sh) |
PA (1) | PA8513601A1 (sh) |
PE (1) | PE20011184A1 (sh) |
PL (1) | PL360780A1 (sh) |
SK (1) | SK12622002A3 (sh) |
SV (1) | SV2002000343A (sh) |
TN (1) | TNSN01040A1 (sh) |
TR (1) | TR200202184T2 (sh) |
WO (1) | WO2001068055A1 (sh) |
YU (1) | YU67202A (sh) |
ZA (1) | ZA200207290B (sh) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA006402B1 (ru) * | 1999-12-23 | 2005-12-29 | Пфайзер Продактс Инк. | Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты) |
CO5271699A1 (es) | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
MXPA03011935A (es) * | 2001-06-22 | 2004-03-26 | Pfizer Prod Inc | Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco. |
EP1404300B1 (en) | 2001-06-22 | 2009-09-30 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
HUP0400281A3 (en) | 2001-06-22 | 2009-11-30 | Pfizer Prod Inc | Pharmaceutical compositions of adsorbates of amorphous drug and process for their preparation |
EP1469830A2 (en) | 2002-02-01 | 2004-10-27 | Pfizer Products Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles |
RU2278659C9 (ru) | 2002-02-01 | 2007-02-20 | Пфайзер Продактс Инк. | Способ получения гомогенных, высушенных распылением твердых аморфных дисперсий лекарственного средства с использованием модифицированной установки сушки распылением |
JP2005523262A (ja) | 2002-02-01 | 2005-08-04 | ファイザー・プロダクツ・インク | 薬物及び親油性ミクロ相形成物質の非晶質分散物の医薬組成物 |
GB0205175D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205170D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205165D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205176D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205162D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
GB0205166D0 (en) | 2002-03-06 | 2002-04-17 | Astrazeneca Ab | Chemical compounds |
US7405210B2 (en) | 2003-05-21 | 2008-07-29 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase |
MXPA06001417A (es) | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas. |
CL2004001884A1 (es) | 2003-08-04 | 2005-06-03 | Pfizer Prod Inc | Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros. |
US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
EP1701704A2 (en) * | 2003-12-31 | 2006-09-20 | Pfizer Products Inc. | Solid compositions of low-solubility drugs and poloxamers |
ES2353309T3 (es) | 2004-03-08 | 2011-03-01 | Prosidion Ltd. | Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa. |
WO2006059163A1 (en) * | 2004-12-02 | 2006-06-08 | Prosidion Limited | Treatment of diabetes with glycogen phosphorylase inhibitors |
DE102005026755A1 (de) * | 2005-06-09 | 2006-12-14 | Basf Ag | Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung |
CN104755504A (zh) * | 2012-08-24 | 2015-07-01 | 陶氏环球技术有限责任公司 | 新的具有高分子量和均匀性的酯化纤维素醚 |
DK3725778T3 (da) | 2012-09-11 | 2021-09-20 | Medivation Prostate Therapeutics Llc | Formuleringer af enzalutamid |
EP3763702B1 (en) * | 2013-07-19 | 2023-12-13 | Siga Technologies, Inc. | Preparation of amorphous tecovirimat dispersions |
CN103709171B (zh) * | 2014-01-20 | 2015-09-16 | 武汉大学 | 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法 |
CN112442022B (zh) * | 2019-09-02 | 2022-05-20 | 承德医学院 | 苯并嗪-4-酮类化合物、其制备方法及医药用途 |
US11291701B1 (en) * | 2021-02-04 | 2022-04-05 | Seed Edibles | Orally disintegrating, sublingual and buccal formulations |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6297269B1 (en) * | 1995-06-06 | 2001-10-02 | Pfizer Inc. | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
CA2342471C (en) * | 1995-06-06 | 2002-10-29 | Judith L. Treadway | Heterocyclecarbonylmethyl amine intermediates |
PT901786E (pt) * | 1997-08-11 | 2007-08-07 | Pfizer Prod Inc | Disperções farmacêuticas sólidas com biodisponibilidade melhorada |
US5998463A (en) * | 1998-02-27 | 1999-12-07 | Pfizer Inc | Glycogen phosphorylase inhibitors |
-
2001
- 2001-03-14 PE PE2001000246A patent/PE20011184A1/es not_active Application Discontinuation
- 2001-03-14 US US09/805,828 patent/US20010053778A1/en not_active Abandoned
- 2001-03-14 AR ARP010101185A patent/AR027656A1/es not_active Application Discontinuation
- 2001-03-15 SV SV2001000343A patent/SV2002000343A/es not_active Application Discontinuation
- 2001-03-15 TN TNTNSN01040A patent/TNSN01040A1/fr unknown
- 2001-03-16 PL PL36078001A patent/PL360780A1/xx not_active Application Discontinuation
- 2001-03-16 EP EP01915586A patent/EP1263414A1/en not_active Withdrawn
- 2001-03-16 JP JP2001566619A patent/JP2003526654A/ja active Pending
- 2001-03-16 OA OA1200200290A patent/OA12232A/en unknown
- 2001-03-16 YU YU67202A patent/YU67202A/sh unknown
- 2001-03-16 SK SK1262-2002A patent/SK12622002A3/sk unknown
- 2001-03-16 CA CA002403241A patent/CA2403241A1/en not_active Abandoned
- 2001-03-16 CO CO01021769A patent/CO5280087A1/es not_active Application Discontinuation
- 2001-03-16 AU AU2001242669A patent/AU2001242669A1/en not_active Abandoned
- 2001-03-16 PA PA20018513601A patent/PA8513601A1/es unknown
- 2001-03-16 BR BR0109189-1A patent/BR0109189A/pt not_active Application Discontinuation
- 2001-03-16 CN CN01806619A patent/CN1418089A/zh active Pending
- 2001-03-16 EE EEP200200530A patent/EE200200530A/xx unknown
- 2001-03-16 AP APAP/P/2002/002621A patent/AP2002002621A0/en unknown
- 2001-03-16 EA EA200200858A patent/EA200200858A1/ru unknown
- 2001-03-16 HU HU0204583A patent/HUP0204583A2/hu unknown
- 2001-03-16 WO PCT/IB2001/000394 patent/WO2001068055A1/en not_active Application Discontinuation
- 2001-03-16 IL IL15132001A patent/IL151320A0/xx unknown
- 2001-03-16 TR TR2002/02184T patent/TR200202184T2/xx unknown
- 2001-03-16 KR KR1020027012009A patent/KR20020081445A/ko not_active Application Discontinuation
- 2001-03-16 CZ CZ20022955A patent/CZ20022955A3/cs unknown
- 2001-03-16 MX MXPA02009097A patent/MXPA02009097A/es unknown
-
2002
- 2002-08-16 IS IS6508A patent/IS6508A/is unknown
- 2002-08-26 BG BG107037A patent/BG107037A/bg unknown
- 2002-09-11 ZA ZA200207290A patent/ZA200207290B/xx unknown
- 2002-09-11 MA MA26810A patent/MA26882A1/fr unknown
- 2002-09-13 NO NO20024386A patent/NO20024386L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP1263414A1 (en) | 2002-12-11 |
IS6508A (is) | 2002-08-16 |
NO20024386D0 (no) | 2002-09-13 |
PL360780A1 (en) | 2004-09-20 |
WO2001068055A1 (en) | 2001-09-20 |
YU67202A (sh) | 2006-01-16 |
HUP0204583A2 (hu) | 2003-04-28 |
MA26882A1 (fr) | 2004-12-20 |
CN1418089A (zh) | 2003-05-14 |
AU2001242669A1 (en) | 2001-09-24 |
IL151320A0 (en) | 2003-04-10 |
CZ20022955A3 (cs) | 2003-09-17 |
CA2403241A1 (en) | 2001-09-20 |
BG107037A (bg) | 2003-04-30 |
EA200200858A1 (ru) | 2003-02-27 |
EE200200530A (et) | 2004-04-15 |
CO5280087A1 (es) | 2003-05-30 |
ZA200207290B (en) | 2003-09-11 |
BR0109189A (pt) | 2003-05-27 |
US20010053778A1 (en) | 2001-12-20 |
JP2003526654A (ja) | 2003-09-09 |
TR200202184T2 (tr) | 2003-01-21 |
OA12232A (en) | 2006-05-10 |
TNSN01040A1 (fr) | 2005-11-10 |
AP2002002621A0 (en) | 2002-09-30 |
KR20020081445A (ko) | 2002-10-26 |
AR027656A1 (es) | 2003-04-09 |
PA8513601A1 (es) | 2004-08-31 |
NO20024386L (no) | 2002-11-13 |
SV2002000343A (es) | 2002-07-03 |
MXPA02009097A (es) | 2003-03-12 |
PE20011184A1 (es) | 2001-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SK12622002A3 (sk) | Farmaceutická kompozícia na báze inhibítorov glykogén fosforylázy | |
JP6932746B2 (ja) | エンザルタミドの製剤 | |
JP6192078B2 (ja) | アピキサバン製剤 | |
CA2582767C (en) | Solid formulation with improved solubility and stability and method for producing said formulation | |
CN101048180B (zh) | 具有改善的溶解度和稳定性的固体制剂和用于制备所述制剂的方法 | |
ES2360064T3 (es) | Dispersión sólida o preparación de dispersión sólida medicinal de un derivado de fenilalanina. | |
JP2022190168A (ja) | グルコキナーゼ活性化剤およびppar受容体活性化剤を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用 | |
JP4787446B2 (ja) | グリブリド組成物 | |
TW200821298A (en) | Pharmaceutical compositions | |
EA028009B1 (ru) | Фармацевтическая композиция с улучшенной биодоступностью | |
KR100717570B1 (ko) | 치료 효과를 신속하게 개시하는 시클로옥시게나제-2저해제 조성물 | |
ES2366394T3 (es) | Composiciones de eprosartán. | |
US20060167069A1 (en) | Pharmaceutical composition of metaxalone with enhanced oral bioavailability | |
KR101441450B1 (ko) | 생체 이용률이 향상된 에프로살탄 고체 분산체, 이의 제조방법 및 용도 | |
KR20090071829A (ko) | 신장질환의 치료 및 예방을 위한 약제 조성물 | |
WO2007102038A1 (en) | Ziprasidone formulations | |
US20240216347A1 (en) | Bezuclastinib formulations | |
RU2391099C2 (ru) | Лекарственное средство, предназначенное для перорального введения, содержащее ингибитор циклооксигеназы-2, и способ его получения |